Blood test may predict who benefits from dust mite allergy treatment
NCT ID NCT07436208
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study tested whether two substances in the blood (sST2 and miR-223) can help predict how well patients with dust mite allergies respond to a six-month course of under-the-tongue immunotherapy (SLIT). Fifty-four patients with moderate-to-severe allergic rhinitis received daily SLIT drops. Researchers measured symptom scores and blood markers before and after treatment to see if changes in sST2 and miR-223 levels matched clinical improvement.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sublingual immunotherapy (SLIT) containing house dust mite extracts
What this could lead to
If successful, this could lead to a simple blood test to predict which patients will benefit from SLIT for dust mite allergies.
What could go wrong
This is a small, early-phase study focused on biomarkers, not treatment effectiveness. The results may not apply to broader populations or lead to a clinical test.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HDM-INDUCED ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zagazig University outpatients clinics
Zagazig, Egypt